OKYO Pharma (NASDAQ:OKYO) Releases Quarterly Earnings Results

OKYO Pharma (NASDAQ:OKYO) posted its earnings results on Friday. The company reported ($2.28) EPS for the quarter, FiscalAI reports.

OKYO Pharma Price Performance

Shares of NASDAQ OKYO opened at $2.05 on Friday. OKYO Pharma has a 1 year low of $1.01 and a 1 year high of $3.35. The firm has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.32.

Institutional Investors Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the company’s stock, valued at approximately $28,000. 2.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on OKYO shares. B. Riley assumed coverage on shares of OKYO Pharma in a research report on Monday, December 8th. They set a “buy” rating and a $5.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of OKYO Pharma in a research report on Thursday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.00.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.